Inkef — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesMission BiocapitalMRL Ventures FundNextech InvestRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.